【獨家代理】巨噬細胞清除劑權威-Formumax氯磷酸二鈉脂質體︱靶點科技北京︱科研級解決方案

技術(shù)文章您現(xiàn)在的位置:首頁 > 技術(shù)文章 > Clodronate Liposomes氯膦酸鹽脂質(zhì)體助力前列腺癌骨轉(zhuǎn)移模型巨噬細(xì)胞研究

Clodronate Liposomes氯膦酸鹽脂質(zhì)體助力前列腺癌骨轉(zhuǎn)移模型巨噬細(xì)胞研究

更新時間:2024-12-14   點擊次數(shù):524次

中文摘要:

轉(zhuǎn)移性去勢抵抗性前列腺癌 (PC) 是 PC 的最后階段,對雄激素剝奪療法 (ADT) 產(chǎn)生耐藥性同時。盡管對疾病機制的理解取得了進展拓展基地,但轉(zhuǎn)移性微環(huán)境對 ADT 耐藥的具體貢獻在很大程度上仍然未知。目前的研究確定引領,巨噬細(xì)胞是患者骨轉(zhuǎn)移性 PC 的主要微環(huán)境成分自動化裝置。使用一種新的體內(nèi)模型,我們證明巨噬細(xì)胞通過誘導(dǎo) ECM 受體基因表達的傷口愈合樣反應(yīng)對恩雜魯胺耐藥至關(guān)重要應用前景。從機制上講有很大提升空間,巨噬細(xì)胞通過細(xì)胞因子激活素 A 驅(qū)動耐藥性,從而在 PC 細(xì)胞中誘導(dǎo)纖連蛋白 (FN1)-整合素 α 5 (ITGA5)-酪氨酸激酶 Src (SRC) 信號級聯(lián)反應(yīng)首次。這種新機制得到了患者轉(zhuǎn)錄組學(xué)數(shù)據(jù)集的生物信息學(xué)分析的強烈支持可能性更大。此外,使用新型特異性抑制劑的巨噬細(xì)胞耗竭或 SRC 抑制顯著抑制了耐藥生長搖籃〖夹g?傊覀兊难芯拷Y(jié)果闡明了巨噬細(xì)胞誘導(dǎo)的轉(zhuǎn)移性 PC 抗雄激素耐藥的新機制推動,以及治療這種致命疾病的有前途的治療方法相對較高。

英文摘要:

Metastatic castration-resistant prostate cancer (PC) is the final stage of PC that acquires resistance to androgen deprivation therapies (ADT). Despite progresses in understanding of disease mechanisms, the specific contribution of the metastatic microenvironment to ADT resistance remains largely unknown. The current study identified that the macrophage is the major microenvironmental component of bone-metastatic PC in patients. Using a novel in vivo model, we demonstrated that macrophages were critical for enzalutamide resistance through induction of a wound-healing–like response of ECM–receptor gene expression. Mechanistically, macrophages drove resistance through cytokine activin A that induced fibronectin (FN1)-integrin alpha 5 (ITGA5)–tyrosine kinase Src (SRC) signaling cascade in PC cells. This novel mechanism was strongly supported by bioinformatics analysis of patient transcriptomics datasets. Furthermore, macrophage depletion or SRC inhibition using a novel specific inhibitor significantly inhibited resistant growth. Together, our findings elucidated a novel mechanism of macrophage-induced anti-androgen resistance of metastatic PC and a promising therapeutic approach to treat this deadly disease.


論文信息:

論文題目: Macrophages promote anti-androgen resistance in prostate cancer bone disease

期刊名稱:JEM- J Exp Med

時間期卷:J Exp Med (2023) 220 (4): e20221007.

在線時間:2022年2月7日

DOI:doi.org/10.1084/jem.20221007


Clodronate Liposomes氯膦酸鹽脂質(zhì)體助力前列腺癌骨轉(zhuǎn)移模型巨噬細(xì)胞研究,Liposoma巨噬細(xì)胞清除劑Clodronate Liposomes見刊于JEM:

image.png


Liposoma巨噬細(xì)胞清除劑Clodronate Liposomes氯膦酸二鈉脂質(zhì)體的材料和方法

image.png

JEM期刊巨噬細(xì)胞清除解決方案 

Drug treatments

Vehicle and enzalutamide (30 mg/kg body weight), SRC inhibitor eCF506 (20 mg/kg body weight) was given via daily oral gavage; L-Clod/PBS (1 mg/mouse, twice a week) were administered by i.v. injection; DT or control Glu52-DT (25 μg/kg body weight, every other day), anti-Ly-6G depleting Abs (200 μg/mouse, every other day), activin-A receptor inhibitor SB-505124 (5 mg/kg body weight, every other day) were delivered by i.p. injection. In some experiments, mice continuously received doxycycline diet (625 mg/kg). Enzalutamide was synthesized by chemical core at Memorial Sloan Kettering Cancer Center; eCF506 was kindly provided by A. Unciti-Broceta; L-Clod/PBS was from Liposoma; anti-Ly-6G Abs (clone #1A8) were from BioxCell; activin-A receptor inhibitor SB-505124 was from Selleckchem; and DT/Glu52-DT was from Sigma-Aldrich.

靶點科技(北京)有限公司

靶點科技(北京)有限公司

地址:中關(guān)村生命科學(xué)園北清創(chuàng)意園2-4樓2層

© 2025 版權(quán)所有:靶點科技(北京)有限公司  備案號:京ICP備18027329號-2  總訪問量:318670  站點地圖  技術(shù)支持:化工儀器網(wǎng)  管理登陸

开平市| 锦州市| 嵩明县| 涞源县| 司法| 双峰县| 安徽省| 洛南县| 高青县| 庆元县| 赤峰市| 图木舒克市| 韩城市| 广昌县| 浑源县| 常熟市| 夏河县| 乌兰察布市| 七台河市| 房山区| 凤冈县| 绥滨县| 稻城县| 廉江市| 翼城县| 洛南县| 延庆县| 集贤县| 邓州市| 外汇| 乳山市| 车致| 临城县| 吴桥县| 黄浦区| 元江| 奉节县| 饶平县| 固始县| 新沂市| 浠水县|